I 
117TH CONGRESS 
2D SESSION 
H. R. 9090 
To amend title XVIII of the Social Security Act to treat certain multimarker 
testing relating to ovarian cancer as reasonable and necessary for cov-
erage under the Medicare program. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 30, 2022 
Ms. DEAN introduced the following bill; which was referred to the Committee 
on Energy and Commerce, and in addition to the Committee on Ways 
and Means, for a period to be subsequently determined by the Speaker, 
in each case for consideration of such provisions as fall within the juris-
diction of the committee concerned 
A BILL 
To amend title XVIII of the Social Security Act to treat 
certain multimarker testing relating to ovarian cancer 
as reasonable and necessary for coverage under the Medi-
care program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Diane Powis Ovarian 
4
Cancer Testing Access Act’’. 
5
VerDate Sep 11 2014 
02:58 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H9090.IH
H9090
kjohnson on DSK79L0C42PROD with BILLS
2 
•HR 9090 IH
SEC. 2. CERTAIN MULTIMARKER TESTING RELATED TO 
1
OVARIAN 
CANCER 
DEEMED 
REASONABLE 
2
AND NECESSARY FOR MEDICARE COVERAGE. 
3
Section 1834 of the Social Security Act (42 U.S.C. 
4
1395m) is amended by adding at the end the following 
5
new subsection: 
6
‘‘(z) CERTAIN MULTIMARKER TESTING RELATED TO 
7
OVARIAN CANCER DEEMED REASONABLE
AND NEC-
8
ESSARY.— 
9
‘‘(1) IN GENERAL.—In the case of a clinical di-
10
agnostic laboratory test that is a multimarker test 
11
related to ovarian cancer that is furnished on or 
12
after January 1, 2023, to an individual who has 
13
been diagnosed with an ovarian adnexal mass, such 
14
test shall be deemed reasonable and necessary for 
15
purposes of section 1862(a)(1)(A) if the physician 
16
who orders such test determines such test is nec-
17
essary for such individual and prescribes, dispenses, 
18
or administers such test for use in accordance with 
19
the labeling approved for such test by the Food and 
20
Drug Administration. 
21
‘‘(2) MULTIMARKER TEST RELATED TO OVAR-
22
IAN CANCER DEFINED.—For purposes of this sub-
23
section, the term ‘multimarker test related to ovar-
24
VerDate Sep 11 2014 
02:58 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H9090.IH
H9090
kjohnson on DSK79L0C42PROD with BILLS
3 
•HR 9090 IH
ian cancer’ means a test that evaluates more than 
1
one tumor marker with respect to ovarian cancer.’’. 
2
Æ 
VerDate Sep 11 2014 
02:58 Oct 19, 2022
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H9090.IH
H9090
kjohnson on DSK79L0C42PROD with BILLS
